Diagnos Laboratorium Utama Tbk. vs Phapros Tbk. — how do they compare? Diagnos Laboratorium Utama Tbk. trades at Rp226 (market cap 308B, 21.3K 24h volume), while Phapros Tbk. trades at Rp258 (market cap 215.04B, 2K 24h volume). The key difference: Diagnos Laboratorium Utama Tbk. is the larger of the two by market cap, and Diagnos Laboratorium Utama Tbk. is more actively traded (21.3K versus 2K). Which is the better fit depends on your goals.
| DGNS | PEHA | |
|---|---|---|
Market Cap | 308B | 215.04B |
Volume | 21.3K | 2K |
Lot | 213 | 20 |
Turnover | 4.86M | 516K |
Average Price | 228.07 | 258 |
Value | 4.86M | 516K |
Indicative Equilibrium Price | 230 | 258 |
Indicative Equilibrium Volume | 110 | 16 |
Trailing returns across standard periods
Latest headlines on both assets
PT Diagnos Laboratorium Utama Tbk (the “Company”) was established in the Republic of Indonesia on August 29, 2007 under framework of the Domestic Capital Investment Law No. 6 Year 1968 based on Deed No.17 dated August 29, 2007, of Martinef, S.H., M.Si., Notary in Bekasi. The Company started its commercial operation in 2008.
Read more on DGNS →PT Phapros Tbk was established under the name of N.V. Pharmaceutical Processing Industries, in short N.V. Phapros, based on Notarial Deed No 54 of Tan A Sioe dated 21 June 1954, which later became PT Pharmaceutical Processing Industries, in short PT Phapros based on Notarial Deed No.43 of E. Pondaag, replacing R.M. Soerojo, dated 5 September 1995, which finally became PT Phapros based on Notarial Deed No. 48 of Prof. Dr. Liliana Tedjosaputro, S.H., M.H., MM., dated 12 April 2006. The Company’s immediate and ultimate parent entity is PT Rajawali Nusantara Indonesia, incorporatedand domiciled in Indonesia.
Read more on PEHA →